Masashi Fujii

Prognostic Impact of Primary Tumor Location on Clinical Outcomes of Metastatic Colorectal Cancer Treated With Cetuximab Plus Oxaliplatin-Based Chemotherapy: A Subgroup Analysis of the JACCRO CC-05/06 Trials

Yu Sunakawa, Wataru Ichikawa, Akihito Tsuji et al. · Clinical Colorectal Cancer · 2016 · 46 citations

Primary Tumor Location, Gastrointestinal Oncology, Medicine +9

Phase 2 study of irinotecan plus cetuximab rechallenge as third-line treatment in KRAS wild-type metastatic colorectal cancer: JACCRO CC-08

Toshiki Masuishi, Akihito Tsuji, Masahito Kotaka et al. · British Journal of Cancer · 2020 · 45 citations · Full text

Differing deregulation of HER2 in primary gastric cancer and synchronous related metastatic lymph nodes

Mitsugu Kochi, Masashi Fujii, Shinobu Masuda et al. · Diagnostic Pathology · 2013 · 42 citations · Full text

Early Tumor Shrinkage and Depth of Response as Predictors of Favorable Treatment Outcomes in Patients with Metastatic Colorectal Cancer Treated with FOLFOX Plus Cetuximab (JACCRO CC-05)

Akihito Tsuji, Yu Sunakawa, Wataru Ichikawa et al. · Targeted Oncology · 2016 · 40 citations

Folfox Plus Cetuximab, Gastrointestinal Oncology, Early Tumor Shrinkage +8

A phase II trial of 1st-line modified-FOLFOXIRI plus bevacizumab treatment for metastatic colorectal cancer harboring RAS mutation: JACCRO CC-11

Hironaga Satake, Yu Sunakawa, Yuji Miyamoto et al. · Oncotarget · 2018 · 34 citations · Full text